Brief: FDA Investigates Death Linked to Adzynma Treatment for Congenital Thrombotic Thrombocytopenic Purpura
21/11/2025 16:42
Nov 21 (Reuters) - FDA: FDA INVESTIGATING DEATH DUE TO NEUTRALIZING ANTIBODIES TO ADAMTS13 FOLLOWING ADZYNMA TREATMENT OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)